ebglyss
Generic: lebrikizumab·Brand: Ebglyss
ebglyss: developed by 1 company · 1 FDA decision.
ebglyss evidence translation
What we can confirm
1 FDA record
What it means
Source-backed records connect ebglyss to LLY; that link alone does not prove the drug works.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
How could ebglyss → LLY affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
For the treatment of adult and adolescent patients 12 years or older with moderate to severe atopic dermatitis (in Europe, in collaboration with Almirall S.A.).
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| ELI LILLY & Co (LLY) For the treatment of adult and adolescent patients 12 years … | Approved |
FDA Decisions1 records
Frequently asked questions
Who is developing ebglyss?
ebglyss is being developed by ELI LILLY & Co.
What is ebglyss's latest FDA decision?
The most recent tracked FDA decision for ebglyss is Approval, dated September 13, 2024.